<DOC>
	<DOCNO>NCT01206647</DOCNO>
	<brief_summary>The purpose study investigate success rate switch insulin therapy metformin &amp; saxagliptin combination patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Investigation Switch From Insulin Therapy Metformin &amp; Saxagliptin Combination Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The follow study base previous clinical trial perform ikfe GmbH Mainz 2006 2007 ( PIOswitch ) . [ 2 ] The purpose trial demonstrate type 2 diabetes patient treated insulin effectively switch pioglitazone/glimepiride combination without loss glycemic control . The study perform 100 patient , 76 finally successfully switch , result cheap convenient therapy indication improve laboratory cardiovascular risk biomarker profile ( Hohberg et al. , Diabetes Obes . Metab . 11:464-471 , 2009 ) . [ 2 ] Glimeperide agent unspecific stimulate effect ß-cell consider accelerate progression disease still control blood glucose . In addition , may cause hypoglycemia . The combination pioglitazone glimepiride select , pioglitazone require approx . 5-6 week develop full anti-diabetic efficacy immediate effect glucose require avoid glycemic deterioration . It tempt speculate combination drug provide ß-cell protection ( like saxagliptin ) drug effectively rapidly lower blood glucose different mechanism action ( metformin ) instead unspecific ß-cell stimulation would result even improve outcome without risk hypoglycemia . The purpose study investigate success rate switch insulin therapy metformin &amp; saxagliptin combination patient type 2 diabetes mellitus .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Combination OAD basal insulin treatment ( BOT ) intensify conventional therapy ( ICT ; &gt; 2 injection basal prandial ) conventional insulin therapy ( CIT ; 1 2 injection basal biphasic ) HbA1c &lt; 7.5 % Age : 1880 year inclusively Duration insulin therapy &gt; 1 year Insulin dose &lt; 120 IU/day Fasting Cpeptide &gt; 0.6 ng/l Fasting glucose ≤ 210 mg/dl Full legal , mental physical ability give inform consent Patient consent general physician inform trail participation Experience self measurement blood glucose &gt; 1 year Type 1 Diabetes mellitus History drug alcohol abuse within last five year prior screen History severe multiple allergy Progressive fatal disease History significant cardiovascular , respiratory , gastrointestinal , hepatic ( ALAT and/or ASAT &gt; 3 time normal reference range ) , neurological , psychiatric and/or haematological disease judge investigator Renal insufficiency history significant renal disease ( creatinine clearance lower 60 ml/min determine use CockroftGoult equation ) . Contraindications study drug include contraindication rescue drug Anamnestic history hypersensitivity study drug drug similar chemical structure Pregnancy breast feed Sexually active woman childbearing potential consistently correctly practice birth control implant , injectables , combine oral contraceptive , hormonal intrauterine device ( IUDs ) , sexual abstinence vasectomise partner Treatment investigational drug within 3 month prior screen Lack compliance similar reason , accord investigator , preclude satisfactory participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>